Investing in early stage biotech companies can be highly profitable for those that get in at an early stage and patient with their investment.
The typical timeline for an FDA approval of a drug from the initial discovery phase all the way to commercialisation is around 10-12 years, but along this journey there are many entry and exit points for investors to make money.
Here is an outline of the lifecycle of a biotech company:
The COVID-19 pandemic has shone a BIG spot-light on the life sciences industry, with everyday investors now familiar with complex technologies behind vaccines, disease transmission, clinical trials and the healthcare industry.
COVID has baked life sciences into the psyche of an entire generation of investors with large-cap pharmaceutical companies like Pfizer becoming household names.
But at its core, people support the life sciences because of the life-changing, and sometimes life-saving, potential of new drugs and technologies.
Life sciences stocks can be tricky to understand, especially if you don’t have a basic knowledge of the underlying science behind the technology. Here we will provide you with a high level understanding of the risks and opportunities with the biotech industry, and explain some of the more complex science in simple terms.
Learn about Biotech Stocks
No articles have been published for this thematic.